A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-30
Target enrollment:
Participant gender:
Summary
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.